Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Taiga Nishihori, MD, Melissa Alsina, MD, Jose Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Rachid Baz, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Jongphil Kim, PhD, Michael Dumala, Joel G. Turner, PhD, Daniel M Sullivan, MD

Blood (2019) 134 (Supplement_1): 3314.

https://doi.org/10.1182/blood-2019-131321

Published: 2019

Journal Articles

Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Correlation with Outcomes in Plasma Cell and Lymphoid Malignancies

Mohammad O Hussaini, MD, Jaya Srivastava, PhD, Lik Wee Lee, PhD, Taiga Nishihori, MD, Bijal Shah, MD, Melissa Alsina, MD, Rachid Baz, MD, Javier Pinilla Ibarz, MD PhD, Kenneth H. Shain, MD PhD

Blood (2019) 134 (Supplement_1): 4654.

https://doi.org/10.1182/blood-2019-129846

Published: 2019

Journal Articles

Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis

Ariel F Grajales-Cruz, MD, Cristian Ivan Rodriguez Arocho, MD, Ashley Rose, MD, Jamie Shapiro, PharmD, Elizabeth Finley-Oliver, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Taiga Nishihori, MD, Leonel Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Melissa Alsina, MD, Rachid Baz, MD

Blood (2019) 134 (Supplement_1): 3183.

https://doi.org/10.1182/blood-2019-129021

Published: 2019

Journal Articles

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

Taiga Nishihori, MD, Rachid Baz, MD, Leonel Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Frederick L. Locke, MD, Jongphil Kim, PhD, Jinming Song, MD PhD, Michael Dumala, Melissa Alsina, MD

Blood (2019) 134 (Supplement_1): 3189.

https://doi.org/10.1182/blood-2019-131451

Published: 2019

Journal Articles

Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Wilson I Gonsalves, MD, Srinivas Devarakonda, MD, Rachid Baz, MD, Natalia Neparidze, MD, Alex A Adjei, MD PhD, Charles Kunos, MD, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 3160.

https://doi.org/10.1182/blood-2019-123399

Published: 2019

Journal Articles

Reinforcement Learning to Optimize the Treatment of Multiple Myeloma

Kenneth H. Shain, MD PhD, Daniel Hart, Ariosto Siqueira Silva, PhD, Raghunandanreddy Alugubelli, MS, Gabriel De Avila, BS, Praneeth Reddy Sudalagunta, PhD, Alexandre Tungesvik, MD, Amit Kulkarni, PhD, Carmelo Blancuicett, PhD MD, Hongyue Dai, PhD, Taiga Nishihori, MD, Jason B. Brayer, PhDMD, Brandon Blue, MD, Melissa Alsina, MD, Rachid Baz, MD, William S. Dalton, PhDMD

Blood (2019) 134 (Supplement_1): 5511.

https://doi.org/10.1182/blood-2019-132234

Published: 2019

Journal Articles

First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

Nizar Bahlis, MD, Rachid Baz, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Shir-Jing Ho, MBBS, FRACP, FRCPA, MClinTrial Res, Annette Juul Vangsted, MD PhD, Philippe Moreau, MD, Simon Gibbs, FRACP, FRCPA, MBBS, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, John Pesko, PhD, Sally Westrup, Jenny Vue, Paulo C. Maciag, MD PhD, Orlando F. Bueno, MD PhD, Jonathan L. Kaufman, MD

Blood (2019) 134 (Supplement_1): 925.

https://doi.org/10.1182/blood-2019-124407

Published: 2019

Journal Articles

Functional Analysis of HDAC11 in Plasma Cell Development and Multiple Myeloma Survival

AGM Mostofa, PhD, Allison Distler, Mark B. Meads, PhD, Eva Sahakian, PhD, John J. Powers, BS, Tuan Nguyen, Melissa Alsina, MD, Taiga Nishihori, MD, Rachid Baz, MD, Javier Pinilla Ibarz, MD, Eduardo Sotomayor, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhD MD

Blood (2018) 132 (Supplement 1): 3223.

https://doi.org/10.1182/blood-2018-99-119119

Published: 2018

Journal Articles

Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)

Rachid Baz, MD, Jeffrey A Zonder, MD, Kenneth H Shain, MD PhD, Melissa Alsina, MD, Jason B. Brayer, PhDMD, Mark Melody, Joel G. Turner, PhD, Jana L Dawson, Jongphil Kim, Daniel M Sullivan, MD

Blood (2017) 130 (Supplement 1): 3095.

https://doi.org/10.1182/blood.V130.Suppl_1.3095.3095

Published: 2017

Journal Articles

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Refractory Multiple Myeloma

Robert Frank Cornell, MD, Adriana C. Rossi, MDMSc, Rachid Baz, MD, Craig C Hofmeister, MDMPH, Chaim Shustik, MD, Joshua R Richter, MD, Christine I Chen, MD FRCP(C), Dan T. Vogl, MD, Erkan Baloglu, William Senapedis, PhD, Joel Ellis, PhD, Tony Williams, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD

Blood (2017) 130 (Supplement 1): 3134.

https://doi.org/10.1182/blood.V130.Suppl_1.3134.3134

Published: 2017

Journal Articles

HDAC11 Is a Candidate Therapeutic Target in Multiple Myeloma

Jason B. Brayer, PhDMD, Allison Distler, Mark B. Meads, PhD, Eva Sahakian, PhD, John J. Powers, BS, Tuan Nguyen, Melissa Alsina, MD, Taiga Nishihori, MD, Rachid Baz, MD, Javier Pinilla-Ibarz, MD PhD, Eduardo Martin Sotomayor, MD, Ken H Shain, MD PhD

Blood (2017) 130 (Supplement 1): 1800.

https://doi.org/10.1182/blood.V130.Suppl_1.1800.1800

Published: 2017

Journal Articles

a Combination of Ex Vivo and Computational Models Predicts Clinical Response in MM Treatment Combinations of Proteasome Inhibitors, Imids, Nuclear Export Inhibitors and Alkylating Agents

Ariosto Silva, PhD, Maria Silva, M.Sc, Timothy Jacobson, B.S., Mark B Meads, PhD, Allison Distler, B.S., Aunshka Collins, BS, Chris Cubitt, PhD, Lia E Perez, MD, Rachid Baz, MD, Dmitri Rebatchouk, PhD, Robert Gatenby, MD, PhD, Kenneth H. Shain, MD PhD

Blood (2016) 128 (22): 3291.

https://doi.org/10.1182/blood.V128.22.3291.3291

Published: 2016

Journal Articles

Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study

Blood (2016) 128 (22): 491.

https://doi.org/10.1182/blood.V128.22.491.491

Published: 2016

Journal Articles

Updated Outcomes of Fludarabine/Melphalan/Bortezomib (Flu/Mel/Vel) Conditioning for Upfront Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma

Taiga Nishihori, MD, Claudio Anasetti, MD, Rachid Baz, MD, Jose L Ochoa-Bayona, MD, Kenneth H. Shain, MD PhD, Ryan Hillgruber, Melissa Alsina, MD

Blood (2016) 128 (22): 5885.

https://doi.org/10.1182/blood.V128.22.5885.5885

Published: 2016

Journal Articles

Promising Prognostic Values of Sequential Gene Expression Profiling in Multiple Myeloma Patients Undergoing Various Systemic Therapy

Yazan Migdady, MD MSc, Taiga Nishihori, MD, Rachid Baz, MD, Ram Thapa, PhD, Youngchul Kim, PhD, Dung-Tsa Chen, PhD, Ryan K Van Laar, PhD, Richard A Bender, MD, Siegel M Erin, PhD MPH, Vonetta Williams, PhD MPH, CTR, Michelle Fouriner, Melissa Alsina, MD, Kenneth H. Shain, MD PhD

Blood (2016) 128 (22): 5648.

https://doi.org/10.1182/blood.V128.22.5648.5648

Published: 2016

Journal Articles

Validation of the Prognostic Significance of Gene Expression Profiling (GEP) Analysis on Myeloma Irrespective of Disease Status or Stage - a Single Center Academic Center Experience -

Taiga Nishihori, MD, Rachid Baz, MD, Ram Thapa, PhD, Youngchul Kim, PhD, Dung-Tsa Chen, PhD, Yazan Migdady, MD, Ryan K Van Laar, PhD, Richard A Bender, MD, Erin M Siegel, PhD MPH, Vonetta Williams, PhD MPH, CTR, Michelle Fournier, Melissa Alsina, MD, Kenneth H. Shain, MD PhD

Blood (2016) 128 (22): 4417.

https://doi.org/10.1182/blood.V128.22.4417.4417

Published: 2016

Journal Articles

A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma

R. Frank Cornell, MD MS, Adriana C Rossi, MD, MSc, Rachid Baz, MD, Craig C Hofmeister, Chaim Shustik, MD, Joshua R. Richter, MD, Christine Chen, MD, Dan T. Vogl, MD, Sharon Shacham, PhD MBA, Erkan Baloglu, PhD MBA, William Senapedis, PhD, Joel Ellis, PhD, Sharon Friedlander, PhD, Cassandra Choe-Juliak, MD, Christopher L Cubitt, PhD, Joel G Turner, PhD, Daniel Sullivan, MD MS, Michael Kauffman, MD PhD

Blood (2016) 128 (22): 4509.

https://doi.org/10.1182/blood.V128.22.4509.4509

Published: 2016

Journal Articles

Feasibility of Implementing Innovative Supportive Care Plans for Symptom Management in Multiple Myeloma

Beth M Faiman, PhD RN, MSN, CNP, AOCN, Paul Jacobsen, PhD, Amy Callahan, DNP, RN, CRNP, AOCNS, Still Nadia, DNP, RN, SaraLena Panzer, BS, Rachid Baz, MD

Blood (2015) 126 (23): 5620.

https://doi.org/10.1182/blood.V126.23.5620.5620

Published: 2015

Journal Articles

Melphalan and XPO1 Inhibitor Combination Therapy for the Treatment of Multiple Myeloma

Joel G Turner, PhD, Jana L Dawson, BS, Steven Grant, MD, Kenneth H. Shain, MD PhD, Yun Dai, MD PhD, Chris Cubitt, PhD, Rachid Baz, MD, Taiga Nishihori, MD, Michael Kauffman, MD PhD, Sharon Shacham, PhD MBA, Daniel M Sullivan, MD

Blood (2014) 124 (21): 2084.

https://doi.org/10.1182/blood.V124.21.2084.2084

Published: 2014

Journal Articles

Subsequent Primary Malignancies Among Multiple Myeloma Patients Treated with or without Lenalidomide

Dana E Rollison, PhD, Rami Komrokji, MD, Ji-Hyun Lee, PhD, Shalaka S Hampras, PhD, William Fulp, Kate Fisher, MA, Rachid Baz, MD, Taiga Nishihori, MD, Marta Olesnyckyj, Laurie Kenvin, BSN, RN, Robert D. Knight, MD, Daniel M Sullivan, MD, Melissa Alsina, MD, William Dalton, PhD MD, Kenneth H. Shain, MD PhD

Blood (2014) 124 (21): 2129.

https://doi.org/10.1182/blood.V124.21.2129.2129

Published: 2014

NARROW

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Correlation with Outcomes in Plasma Cell and Lymphoid Malignancies

Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Reinforcement Learning to Optimize the Treatment of Multiple Myeloma

First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

Functional Analysis of HDAC11 in Plasma Cell Development and Multiple Myeloma Survival

Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Refractory Multiple Myeloma

HDAC11 Is a Candidate Therapeutic Target in Multiple Myeloma

a Combination of Ex Vivo and Computational Models Predicts Clinical Response in MM Treatment Combinations of Proteasome Inhibitors, Imids, Nuclear Export Inhibitors and Alkylating Agents

Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study

Updated Outcomes of Fludarabine/Melphalan/Bortezomib (Flu/Mel/Vel) Conditioning for Upfront Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma

Promising Prognostic Values of Sequential Gene Expression Profiling in Multiple Myeloma Patients Undergoing Various Systemic Therapy

Validation of the Prognostic Significance of Gene Expression Profiling (GEP) Analysis on Myeloma Irrespective of Disease Status or Stage - a Single Center Academic Center Experience -

A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma

Feasibility of Implementing Innovative Supportive Care Plans for Symptom Management in Multiple Myeloma

Melphalan and XPO1 Inhibitor Combination Therapy for the Treatment of Multiple Myeloma

Subsequent Primary Malignancies Among Multiple Myeloma Patients Treated with or without Lenalidomide

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only